Amal Therapeutics SA (spin-off from the University of Geneva) is a Swiss biotech start-up company. The company is developing a recombinant protein based vaccine with proprietary cell penetrating peptides as vector.
Amal Therapeutics SA
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/amal-therapeutics” connections=”true” suffix=””]
Its proprietary cell penetrating peptide platform is a engineered recombinant vaccine based on a fusion protein of a Cell Penetrating Peptides (CPPs) with a multi-antigenic chimeric cargo. The cargo is a rationally designed chimeric protein with various CD8+ and CD4+ epitopes. The resulting vaccines promote an integrated and multi-epitopic immune response.
AMAL’s most advanced cancer targeting asset is ATP128, a preclinical stage therapeutic vaccine for the treatment of colorectal cancer. It is expected to enter clinical trials in 2019.
In July 2014, Amal Therapeutics partners with TransCure bioServices (preclinical CRO) to develop a glioblastoma vaccine utilizing TransCures humanized mouse models.
In Sep 2017, AMAL Therapeutics raised ã8 Mn (CHF 8.8 Mn) in the first tranche of its Series B financing round, co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund.
In Mar 2016, AMAL completed CHF 3 Mn Series A financing round led by Boehringer Ingelheim Venture Fund, VI Partners and High-Tech Gr»nderfonds. Earlier, in Feb 2014, Amal raises seed round funding from Boehringer Ingelheim Venture Fund and High-_?Tech Gr»nderfonds to develop therapeutic cancer vaccines.